chromogenic in situ hybridization

Bright-field in situ hybridization is an alternative to FISH and uses a combination of in situ methodology and a peroxidase-mediated chromogenic substrate such as diaminobenzidine [chromogenic in situ hybridization (CISH)] or multimer technology coupled with enzyme metallography [silver-enhanced in situ hybridization (SISH)] to create a marker visible under bright-field microscopy.

CISH was introduced into diagnostic testing in Australia in October 2006. SISH methodology is a more recent introduction into the testing repertoire. An evaluation of CISH and SISH performance to assess patient outcome were performed using tissue microarrays.

Fluorescence in situ hybridization (FISH) is regarded as the gold standard method for detecting HER2 gene amplification.

Chromogenic in situ hybridization (CISH) is a promising alternative to FISH because CISH has the advantages of being a method evaluated by bright-field microscopy and the generated chromogenic signals are also stable.

Dual-color CISH

It is possible by dual-color CISH method to demonstrate HER2 genes and chromosome 17 genes, in the same tissue section and reliably assess HER2 status. The CISH method is a very promising alternative to the FISH method. (19430295)

Targets

 HER2 / ERBB (21052003, 18945356, 18945356, 19430296, 19430295)
 EGFR (18382350)

References

 Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice. Farshid G, Armes JE, Bell R, Cummings M, Fox S, Francis G, Haswell M, Morey A, McCue G, Raymond W, Robbins P, Bilous M. Diagn Mol Pathol. 2010 Dec;19(4):187-93. PMID: 21052003

 Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M, Walk E, Penault-Llorca F, Kurosumi M, Dietel M, Wang L, Loftus M, Pettay J, Tubbs RR, Grogan TM. Diagn Pathol. 2008 Oct 22;3:41. PMID: 18945356 [Free]

 Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M, Walk E, Penault-Llorca F, Kurosumi M, Dietel M, Wang L, Loftus M, Pettay J, Tubbs RR, Grogan TM. Diagn Pathol. 2008 Oct 22;3:41. PMID: 18945356 [Free]

 Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Francis GD, Jones MA, Beadle GF, Stein SR. Diagn Mol Pathol. 2009 Jun;18(2):88-95. PMID: 19430296

 The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Pedersen M, Rasmussen BB. Diagn Mol Pathol. 2009 Jun;18(2):96-102. PMID: 19430295

 Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH). Fischer I, de la Cruz C, Rivera AL, Aldape K. Diagn Mol Pathol. 2008 Dec;17(4):227-30. PMID: 18382350